Generic Name: raloxifene
Drug Class: Hormone Therapy Medications
Company: Eli Lilly
Approval Status: Approved
Generic Version Available: Yes
Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.
The female hormone estrogen promotes the growth of hormone receptor-positive breast cancer. Evista works blocking these receptors and preventing estrogen from binding to cancer cells. It has selective activity against breast cancer while having estrogen-like activity elsewhere in the body. Like estrogen, it can help reduce bone loss after menopause. It was approved in 1997.
Evista is taken as a once-daily tablet.
Common side effects include hot flashes, muscle and joint pain and swelling. Potential serious side effects may include stroke, blood clots and pulmonary embolism. Evista should not be used during pregnancy.
Patient Assistance Program Info: http://www.lillycares.com
Last Reviewed: December 6, 2018